Apyx Medical Corporation reported a total revenue of $52.8 million for the fiscal year ending December 31, 2025, marking a 9.9% increase from $48.1 million in 2024. The Surgical Aesthetics segment, which includes the company's Helium Plasma Technology products, contributed $45.3 million, a 17.4% increase from the previous year. This growth was primarily driven by the commercial launch of the AYON Body Contouring System in September 2025. However, the OEM segment saw a decline in revenue, dropping 20.9% to $7.5 million, attributed to decreased sales volume to existing customers.
The company incurred a loss from operations of $6.4 million in 2025, a significant improvement compared to the $18.8 million loss reported in 2024. Apyx Medical's cash and cash equivalents stood at $31.7 million as of December 31, 2025, with net cash used in operating activities decreasing to $8.0 million from $18.0 million in the prior year. The reduction in operating losses was aided by cost-saving measures implemented in late 2024, which included a workforce reduction of nearly 25% and other operational efficiencies that lowered annual operating expenses to below $40 million.
Strategically, Apyx Medical has focused on expanding its product offerings and market presence. The AYON system, which received FDA clearance in May 2025, is designed to provide comprehensive body contouring solutions and integrates multiple functions for surgeons. The company also launched Renuvion in China in July 2025, following regulatory approval, and plans to expand its product availability in new markets. Additionally, Apyx Medical has submitted a premarket notification to the FDA for label expansion of AYON to include power liposuction, with anticipated clearance in the second quarter of 2026.
Operationally, Apyx Medical reported selling approximately 84,000 single-use handpieces in 2025, down from 94,000 in 2024. The company has also been actively managing its supply chain and inventory, with total inventories increasing to $8.6 million from $7.6 million year-over-year. The company’s workforce was reported at 205 full-time employees as of December 31, 2025, reflecting the impact of its restructuring efforts.
Looking ahead, Apyx Medical aims to enhance physician support, expand regulatory approvals, and generate consumer interest in its products, particularly in light of the growing demand for body contouring solutions. The company acknowledges the ongoing challenges posed by market conditions, including the impact of GLP-1 medications on the aesthetic surgery market, but remains optimistic about the potential for future growth driven by its innovative product offerings and strategic initiatives.
About Apyx Medical Corp
Apyx Medical Corporation develops and manufactures advanced energy medical devices featuring proprietary Helium Plasma Technology, marketed as Renuvion for cosmetic surgery and J-Plasma for hospital surgical applications. Serving plastic surgeons and medical professionals globally, the company offers electrosurgical generators, handpieces, and accessories that deliver precise tissue treatment with controlled heat. Its business model combines direct sales, distributor networks, OEM manufacturing, and a strong focus on innovation, clinical support, and intellectual property protection.
About 10-K Filings
A 10-K form is a comprehensive annual report that public companies in the United States must file with the SEC, providing a detailed overview of the company's financial condition, performance, and business strategies.
Key points about the 10-K:
- Frequency: Filed annually, typically within 60 to 90 days after the end of the company's fiscal year.
-
Content: It includes:
- Detailed financial statements audited by an independent accounting firm
- Management's Discussion and Analysis (MD&A) of financial condition and results
- Description of the company's business, properties, and legal proceedings
- Risk factors and market risks
- Executive compensation and corporate governance information
- Importance: Considered the most comprehensive and important document a public company files with the SEC.
- Length: Often exceeds 100 pages due to its extensive and detailed nature.
Our Methodology
AssetRoom is committed to providing timely summaries of news from public companies. We use AI to generate these summaries quickly, but they are not reviewed by human experts.
Our method:
- Data Collection: We continuously monitor for new filings (currently limited to US-listed stocks).
- AI-Powered Analysis: Our advanced AI system processes each filing, identifying key information and extracting relevant data.
- Summary Generation: The AI creates a concise, easy-to-understand summary of the filing, highlighting the most important points.
- Publication: The summary is immediately published on our platform, allowing users instant access to the latest information.
- Email users: We distribute round-up emails according to our users preferences, keeping them in the loop with the companies they follow.
Feedback & Corrections
Spot an error or have a suggestion? Contact us.